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Abstract
Background/Objective—Rapid postnatal weight gain is a potentially modifiable risk factor for 
obesity and metabolic syndrome. To identify markers of rapid infancy weight gain and childhood 
obesity, we analyzed the metabolome in cord blood from infants differing in their postnatal weight 
trajectories.
Methods—We performed a nested case-control study within Project Viva, a longitudinal cohort 
of mothers and children. We selected cases (n=26) based on top quartile of change in weight-for-
age 0-6 mo and BMI >85th percentile in mid-childhood (median 7.7 years). Controls (n=26) were 
age- and sex-matched, had normal postnatal weight gain (2nd or 3rd quartile of change in weight-
for-age 0-6 mo) and normal mid-childhood weight (BMI 25th-75th percentile). Cord blood 
metabolites were measured using untargeted LC/MS; individual metabolites and pathways 
differing between cases vs. controls were compared in categorical analyses. We adjusted 
metabolites for maternal age, maternal BMI, and breastfeeding duration (linear regression), and 
assessed whether metabolites improved the ability to predict case-control status (logistic 
regression).
Results—Of 415 detected metabolites, 16 were altered in cases vs. controls (T-test, nominal 
P<0.05). 3 metabolites were related to tryptophan: serotonin, tryptophan betaine, and tryptophyl 
leucine (46%, 48% and 26% lower in cases, respectively, P<0.05). Mean levels of 2 methyl 
donors, dimethylglycine and N-acetylmethionine, were also lower in cases (18% and 16% 
respectively, P=0.01). Moreover, the glutamine:glutamate ratio was reduced by 33% (P<0.05) in 
cases. Levels of serotonin, tryptophyl leucine, and N-acetylmethionine remained significantly 
different after adjustment for maternal BMI, age, and breastfeeding. Adding metabolite levels to 
logistic regression models including only clinical covariates improved the ability to predict case 
vs. control status.
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Conclusions—Several cord blood metabolites are associated with rapid postnatal weight gain. 
Whether these patterns are causally linked to childhood obesity is not clear from this cross-
sectional analysis, but will require further study.
Introduction
Early infancy represents a window of developmental plasticity during which environmental 
exposures can modulate chronic disease risk. Accelerated postnatal weight gain trajectories 
are associated with increased risk of diabetes, obesity, and cardiovascular disease both in 
humans (1-3) and mammalian models (4;5). These data have implications for public health, 
as the postnatal period offers a window during which optimizing nutrition and/or growth 
rates could reap lifelong benefits. Thus, identifying early markers of rapid infancy weight 
gain, a potentially modifiable risk factor for obesity and type 2 diabetes (T2D), may 
eventually permit interventions targeting children at high risk for metabolic disease.
Metabolomic analysis allows comprehensive quantification of hundreds of nutrients, 
metabolic intermediates, and small molecules from biological samples and has proven a 
powerful tool for biomarker discovery. Recent metabolomic analyses have linked higher 
plasma levels of branched-chain and aromatic amino acids to subsequent development of 
T2D in adolescents and adults (6;7). We are not aware of any studies linking cord blood 
metabolomics to obesity or its early life risk factors. However, the cord blood metabolome 
does appear to be related to important clinical outcomes. For example, distinct cord blood 
signatures characterize infants with intrauterine growth restriction, notably higher 
phenylalanine and citrulline, and lower glutamine, choline, and glucose (8). Reductions in 
cord blood phospholipids have also been reported to predict early childhood type 1 diabetes 
risk (9).
We hypothesized that the cord blood metabolome would differ in newborns with 
subsequently development of early childhood obesity. To identify early biomarkers of rapid 
weight gain during infancy and childhood, we analyzed plasma metabolomic patterns in 
venous umbilical cord blood collected at delivery from infants who subsequently 
experienced or did not experience accelerated postnatal weight gain and childhood obesity.
Methods
Study population and measurements
We analyzed a subset of participants in Project Viva, a longitudinal cohort study of mothers 
and children. Detailed experimental protocols for Project Viva have been previously 
published (10). We recruited pregnant women during the first trimester from 8 obstetric 
offices of Harvard Vanguard Medical Associates in Boston, MA, between 1999 and 2002. 
Eligibility criteria included singleton pregnancy, ability to answer questions in English, and 
initial prenatal visit before 22 weeks gestation. In-person study visits occurred at recruitment 
(median 9.9 weeks gestation), mid-pregnancy (median 28.1 weeks gestation), just after 
delivery, during infancy (median 6.3 months), early childhood (median 3.3 years), and mid-
childhood (median 7.7 years); detailed survey data were collected annually at intervening 
time points. At each visit, research assistants measured weight with a digital scale, and 
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length (newborn, infancy) or height (early childhood, mid-childhood) using a calibrated 
stadiometer. We used 2000 CDC reference data (http://www.cdc.gov/growthcharts/) to 
calculate weight-for-age Z-scores and BMI percentiles. We assessed body composition in 
mid-childhood by dual-energy X-ray absorptiometry (DXA, Discovery A, Hologic, Bedford, 
MA). The DXA scanner was monitored for quality control daily by scanning a standard 
synthetic spine. We used Hologic software QDR version 12.6 for analysis. A single trained 
investigator checked all scans for positioning, movement, and artifacts, and defined body 
regions for analysis. Intrarater reliability on duplicate measurements was high (r=0.99).
We obtained written informed consent from the mother at each encounter and verbal assent 
from children at the mid-childhood visit. The Harvard Pilgrim Health Care Institutional 
Review Board approved all procedures.
Identification of cases and controls
We identified 26 cases based on accelerated early postnatal weight gain, defined as the top-
quartile of change in weight for age from 0-6 months in Project Viva and overweight status 
(BMI>85th percentile according to CDC 2000) in mid-childhood. Controls were sex-
matched and selected based on normal early postnatal weight gain, defined as the 2nd or 3rd 
quartile of change in weight for age from 0-6 months in Project Viva and normal weight 
(BMI between 25th and 75th percentile, CDC 2000) in mid-childhood.
Cord blood collection
Using a standard protocol, obstetricians and midwives collected blood from the umbilical 
cord vein at delivery. Whole blood was collected in EDTA tubes, refrigerated for <24 hours, 
and centrifuged at 2000 rpm at 4°C for 10 min. Plasma aliquots were stored in liquid 
nitrogen until shipment on dry ice to Metabolon (Durham, NC) for metabolomic analysis. 
Aliquots of cord blood were also used for analysis of adiponectin and leptin concentrations 
using commercial assay kits (RIA, Linco Research Inc., St. Charles, MO).
Metabolomic analysis
We performed untargeted metabolomic profiling using multi-platform mass spectroscopy 
(Metabolon, Durham, NC). Detailed descriptions of sample preparation, mass spectroscopy, 
and automated metabolite identification procedures have been previously published (11;12). 
We obtained semi-quantitative concentrations (expressed in arbitrary units) for 415 known 
biochemicals. We replaced undetectable values with 0.5*minimum value for each 
metabolite. We then log2-transformed the metabolite concentrations to minimize the 
influence of outliers. We excluded from the analysis 27 metabolites with undetectable values 
in >50% of samples.
Statistical analysis
To determine which cord blood metabolites differed in cases vs. controls, we calculated 
fold-changes for each biochemical (calculated by exponentiating the mean log2-metabolite 
level in cases, divided by the exponentiated mean log2-metabolite level in controls) and 
performed 2-sided unpaired Student’s T-tests using JMP Pro v10 software (SAS, Cary, NC). 
We calculated false discovery rate Q-values to account for multiple comparisons (http://
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genomics.princeton.edu/storeylab/qvalue/) (13); Q-value < 0.25 was considered significant. 
We next performed metabolite set enrichment analysis to identify pathways enriched among 
the most differentially regulated metabolites between cases and controls (MetaboAnalyst 
2.0, www.metaboanalyst.ca) (14).
To assess the overall variability within our dataset, we performed principal components 
analysis (PCA) using R (www.r-project.org), including only imputed, log-transformed 
metabolite concentrations and case/control status. Then, to determine to what extent the 
metabolome distinguished cases from controls, we performed unsupervised hierarchical 
clustering (MetaboAnalyst 2.0) (14). To assess which metabolites contributed most strongly 
to distinguishing cases from controls, we next used partial-least-squares discriminant 
analysis (PLS-DA) using R.
We adjusted for potential confounders through multivariate linear and logistic regression 
analysis (JMP Pro v 10, SAS, Cary, NC). After determining which clinical covariates were 
associated with case vs. control status using bivariate logistic regression, we next built 
multivariable models including those covariates with the strongest association with case-
control status, namely, maternal pre-pregnancy BMI, maternal age, breastfeeding duration, 
and paternal BMI. Because paternal BMI did not contribute to the predictive power (whole-
model R2) of the multivariable models, we omitted it from subsequent models. We used 
linear regression to calculate metabolite concentrations adjusted for maternal BMI, maternal 
age, and breastfeeding duration. To test whether cord blood metabolite levels were 
associated with odds of case vs. control status after adjusting for clinical covariates, we then 
built models incorporating individual metabolites in addition to maternal BMI, maternal age 
and breastfeeding duration.
Results
Demographic, pregnancy, and hormonal characteristics in infants with accelerated 
postnatal weight gain
Mothers of cases were younger than controls (29.9±5.4 vs. 34.9±4.4 years), and had higher 
pre-pregnancy BMI (27.9±6.7 vs. 23.6±3.8 kg/m2). Paternal BMI was also higher among 
cases (27.6±3.7 vs. 25.3±3.5 kg/m2). 13 (50%) of the cases were non-white, vs. 7 (27%) of 
the controls.
Case infants tended to have lower birth weight (3275±458 vs. 3487±349 g), and a trend for 
lower birth weight Z-scores adjusted for gestational age and sex (−0.19 0.79 vs. 0.11±0.67). 
As expected based on our selection strategy, cases had significantly higher weight for age Z-
score in infancy (1.25±0.86 vs. 0.26±0.59, P<0.0001) and higher BMI percentile in mid-
childhood (95.5±4.7 vs. 51.5±15.5, P<0.0001). In mid-childhood, both total fat mass and 
lean mass were higher in cases vs. controls. Cases had a shorter duration of breastfeeding 
(4.0±3.1 vs. 8.2±4.0 months, P<0.001). Demographic, pregnancy, and infancy 
characteristics are summarized in Table 1.
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Unsupervised analysis: cord metabolites do not clearly discriminate cases and controls
We detected a total of 415 biochemicals, including 99 amino acids, 33 carbohydrates, 18 
cofactors and vitamins, 42 xenobiotics, and 153 lipids in cord blood (full list, Supplemental 
Table 1). To better understand the structure of the cord blood metabolome in cases vs. 
controls, we used unsupervised principal components analysis (PCA) to identify metabolites 
contributing the most to observed differences in the dataset. PCA did not clearly separate the 
two groups (Supplemental Figure 1A). Similarly, unsupervised hierarchical clustering did 
not fully separate cases from controls, although visual inspection suggests that subsets of 
cases and controls did cluster together (Supplemental Figure 1B). We next used partial least 
squares discriminant analysis (PLS-DA) to identify metabolites predictive of case vs. control 
status. Two distinct clusters were observed (Supplemental Figure 1C), but the model was not 
statistically significant, with permuted p-value = 0.11.
Individual cord blood metabolites associated with case vs. control status
Mean levels of 16 biochemicals were significantly different between cases and controls 
(nominal P<0.05); none reached a false-discovery-rate (FDR) threshold of <0.25. 2 
metabolites, threonine and homostachydrine, were significantly higher in cases, while 14 
metabolites were lower (Figure 1A-D and Table 2). The metabolite with the greatest fold-
reduction (50% lower, P=0.01) in cases was 4-vinylphenol sulfate. Two of the most 
significantly reduced metabolites in cases, dimethylglycine (18% lower, P=0.01) and N-
acetyl methionine (16% lower, P=0.01), are methyl donors involved in one-carbon 
metabolism (Figure 1B). Three of the metabolites with lower levels in cases vs. controls are 
related to tryptophan or its metabolism: tryptophan betaine (48% lower, P=0.03), tryptophyl 
leucine (26% lower, P=0.03), and serotonin (46% lower, P=0.02, Figure 1C). Three of the 
top-ranking metabolites were xenobiotics found in plants, including homostachydrine 
(abundant in alfalfa and citrus; 54% higher in cases, P=0.007), N-methyl proline (citrus; 
33% higher in cases, P=0.04), and tryptophan betaine (legumes).
Given that several clinical characteristics linked to childhood obesity risk differed between 
cases and controls (i.e. maternal BMI, maternal age, and breastfeeding duration), we next 
used linear regression to calculate metabolite concentrations adjusted for these potential 
confounders. A total of 17 metabolites were significantly altered in cases vs. controls at 
adjusted P<0.05 (Table 2B). Several of the metabolites identified in our raw comparison of 
cases vs. controls remained significant after adjustment, including homostachydrine, 4-
vinylphenol sulfate, N-acetylmethionine, serotonin, tryptophyl leucine, and 1-stearoyl-GPE 
(adjusted P<0.05). Of note, 5 of the 17 top-ranking metabolites in the adjusted analysis were 
related to tryptophan, including serotonin, tryptophan, tryptophyl leucine, N-
acetyltryptophan, and indolelactate. We also observed lower levels of metabolites related to 
branched chain amino acids, including leucine, alpha-hydroxyisovalerate, and alpha-
hydroxyisocaproate, in cases.
Pathway analysis of cord metabolites associated with case vs. control status
To test whether cord blood metabolites that differed in cases with accelerated postnatal 
weight gain vs. controls belonged to known biological pathways, we performed metabolite 
set enrichment analysis. Several pathways were enriched (false discovery rate <0.25). The 
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most significantly enriched pathways were “Tryptophan Metabolism” (P=0.02) and 
“Excitatory neural signaling through 5HTR4/6/7 and serotonin” (P=0.02) (Supplemental 
Table 2). Also highly enriched were pathways associated with metabolism of other amino 
acids, including aspartate and beta-alanine (P=0.02 and P=0.03, respectively). Metabolites 
involved in metabolism of betaine, an organic osmolyte and methyl donor, were also 
significantly enriched (P=0.02).
Given that several pathways related to amino acid metabolism were altered, we examined 
the ratio of glutamine to glutamate, which reflects glutamine synthase activity, and has been 
linked to risk of obesity, insulin resistance and diabetes in humans (15). Plasma from cases 
tended to have a lower glutamine : glutamate ratio (P=0.08), a difference that became 
significant (33% lower, P=0.046) after excluding an outlier in the control group with 
glutamine levels >6 standard deviations below the mean (Figure 1E).
Cord blood metabolites predicted case vs. control status above and beyond clinical risk 
factors
Because infants with accelerated postnatal weight gain and overweight status in mid-
childhood (‘cases’) differed from controls with regard to maternal pre-pregnancy BMI, 
maternal age, breastfeeding duration, and other covariates that could influence postnatal 
obesity risk, we next investigated whether cord blood metabolites were associated with the 
odds of being a case independent of these potential confounders. We therefore used logistic 
regression to identify clinical covariates predictive of case vs. control status and then tested 
whether cord blood metabolite levels independently contributed to the risk of being a case 
above and beyond the clinical risk factors. Using bivariate logistic regression, we found that 
breastfeeding duration (OR: 0.74, 95%CI: 0.62-0.89, P=0.001) and maternal age (OR: 0.81, 
95%CI: 0.71-0.93, P=0.003) were associated with reduced odds of being a case, whereas 
pre-pregnancy maternal BMI (OR: 1.19, 95%CI: 1.04-1.36, P=0.01) and paternal BMI (OR: 
1.21, 95%CI: 1.01-1.45, P=0.04) were the most significant positive predictors of case vs. 
control status (Table 3A). We next built stepwise multivariate logistic regression models, 
and found that breastfeeding duration, maternal age, and pre-pregnancy BMI were 
independently associated with case vs. control status, whereas the addition of covariates 
such as newborn weight, race, sex, and paternal BMI contributed little to the strength of the 
models. We sequentially added each of the top-ranking metabolites identified in our adjusted 
and unadjusted analyses (Table 2A/2B) to these logistic regression models to determine 
whether cord blood metabolites improved the ability to predict case vs. control status.
Many of the top-ranking metabolites substantially improved the strength of the logistic 
regression models. For example, adding cord blood levels of N-acetyl methionine to a model 
including breastfeeding duration, maternal age, and pre-pregnancy BMI improved the ability 
to discriminate cases from controls (R-squared for model without metabolite: 0.39, 
P<0.0001; R-squared for model with N-acetyl methionine: 0.54, P<0.0001, Table 3B). 
Similarly, adding metabolites related to tryptophan (e.g. tryptophyl leucine, tryptophan, 
indolelactate) also improved prediction ability, as did metabolites related to branched chain 
amino acid metabolism (e.g. alpha-hydroxyisocaproate, alpha-hydroxyisovalerate, leucine). 
Moreover, the associations between such metabolites and the odds of case vs. control status 
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were independent of the clinical covariates (Table 3B). Only the metabolites that improved 
the strength of the logistic regression models and contributed independently to the odds of 
case/control status are included in Table 3B.
Discussion
Among cases with rapid infancy weight gain and overweight in mid-childhood vs. controls 
without rapid weight gain and no childhood overweight, we found that mean levels of 16 
cord blood metabolites were significantly different. Pathway analysis revealed that 
biochemicals related to tryptophan and one-carbon metabolism were enriched among the 
differentially-regulated metabolites. Moreover, the cord blood ratio of glutamine:glutamate 
was lower in cases vs. controls. Our analysis is limited by the fact that several clinical 
characteristics associated with childhood BMI, including maternal age, maternal BMI, and 
breastfeeding duration, differed between cases and controls. While many of the differentially 
regulated metabolites survived adjustment for identified covariates, we cannot exclude the 
possibility that additional factors related to maternal metabolism or breastfeeding that we 
did not measure or adjust for might have contributed to the observed differences. Moreover, 
no individual metabolites in our categorical analysis had significant false discovery rates. 
Logistic regression demonstrated that maternal age, pre-pregnancy BMI, and breastfeeding 
duration were associated with increased odds of being a case vs. a control; adding cord 
blood metabolites related to one-carbon and tryptophan metabolism to these prediction 
models improved the ability to differentiate cases with early childhood obesity risk from 
controls. Our results therefore suggest that cord blood metabolic signatures may be 
associated with early childhood obesity trajectories. However, the cross-sectional nature of 
our analysis and the potential influence of maternal or dietary factors on the cord 
metabolome preclude assessment of whether these metabolic pathways are causally related 
to infancy weight gain.
While many groups have used metabolomic profiling to identify disease biomarkers in 
adults at risk for insulin resistance (15), diabetes (7), and cardiovascular disease (16), few 
studies have examined plasma metabolomic patterns in infancy or childhood (6;17;18). A 
recent study found that cord blood phospholipids were predictive of early-onset type 1 
diabetes (9). Cord blood metabolomic markers are also linked to neonatal hypoxia, 
prematurity, and intrauterine growth retardation (8;19;20). To our knowledge, our study is 
the first to characterize the cord blood metabolome of infants at risk for childhood obesity, 
prior to obesity onset.
Our data suggest that differences in maternal diet are associated with postnatal weight gain 
trajectories in infancy. Indeed, several of the top-ranking metabolites altered between cases 
and controls were food constituents – mostly plant products. For example, homostachydrine, 
higher in cases, is linked to dietary intake of citrus (21) and dairy products (22); N-methyl 
proline, reduced in cases, is linked to citrus consumption (22); 4-vinylphenol sulfate, lower 
in cases, is a styrene metabolite found in wine, cider, berries and peanuts (22); and 
tryptophan betaine, reduced in cases, is abundant in legumes. Moreover, pyridoxate, a 
vitamin B6 metabolite reduced in cases, is linked to multivitamin consumption, and maltose, 
reduced in cases, is a disaccharide abundant in many foods. Another metabolite with lower 
Isganaitis et al. Page 7
Int J Obes (Lond). Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
levels in cases, 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF), is a uremic toxin, 
but also correlates with dietary intake of green vegetables, garlic, onions, and fish (22). 
CMPF has been described to compete with penicillin for binding to the renal tubule 
transporter rOat3; it is unclear whether a trend for higher penicillin G levels in cases vs. 
controls (fold-change: 2.83, P=0.22, not shown) might have contributed to observed 
reductions in CMPF in cases (23). Interestingly, elevations in CMPF have recently been 
described in the setting of impaired glucose tolerance, GDM, and T2DM; in mice, CMPF 
directly inhibits beta cell insulin secretion (24). Such data contrast with our observation of 
decreased CMPF levels in cord blood from cases despite a similar prevalence of GDM in 
both groups. Future studies will be required to assess transplacental passage and metabolism 
of this potentially important metabolite. Taken together, the numerous food and plant 
components among the most differentially regulated metabolites between cases and controls 
are largely consistent with the literature linking maternal dietary patterns (both during and 
after pregnancy) with offspring obesity (25).
A unique feature of our data is that it implicates specific nutrients and metabolites as 
potential contributors to early childhood obesity risk. To what degree such signatures might 
stem from differences in maternal BMI, which differed in cases and controls, or from 
differences in feeding/fasting in the hours leading up to delivery, vs. long-term dietary 
patterns, is not clear.
Our results point to an association between cord blood levels of metabolites related to 
tryptophan and one-carbon metabolism, and accelerated postnatal weight gain. Three of the 
16 significantly altered metabolites in cases vs. controls are structurally related to or 
metabolized from tryptophan. Moreover, 2 of the 16 metabolites that differed in cases and 
controls were methyl donors, and metabolite set enrichment analysis revealed “Betaine 
Metabolism” as one of the top-ranking pathways altered between cases vs. controls (betaine 
is diet-derived methyl donor). Associations of biochemicals related to tryptophan and 
obesity trajectories in our analysis are intriguing in light of the multiple lines of evidence 
linking serotonin to appetite regulation, beta cell development, and brown adipose tissue 
thermogenesis, as well as links between diet-derived tryptophan betaine and sleep regulation 
(26-30). Metabolites involved in one-carbon metabolism (e.g. dimethylglycine, methionine, 
betaine) have also recently been implicated in the pathogenesis of obesity, insulin resistance, 
and fatty liver (15)(31), in addition to an established role in the regulation of epigenetic 
marks (e.g. DNA and histone methylation). However, it would be premature to conclude, 
from our analysis of cord blood, that these metabolite patterns are causally linked to obesity 
pathogenesis. Rather, these relationships may result from differences in dietary patterns 
among the mothers of cases, or from other differences between cases and controls that were 
not accounted for in our adjusted analyses. It will be important for future studies to further 
explore whether tryptophan or one-carbon metabolism are linked to childhood obesity risk.
Because our categorical and pathway analyses highlighted differences in the levels of 
several amino acids and their derivatives, we examined whether the glutamine:glutamate 
ratio – a marker for the activity of glutamine synthetase – differed in cases vs. controls. 
Cases had a reduced glutamine:glutamate ratio. Other groups have described reductions in 
cord blood glutamine levels and in the glutamine:glutamate ratio in LBW infants (8;32), but 
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this has not, to our knowledge, previously been assessed in the setting of early childhood 
obesity risk. Plasma glutamine levels fluctuate in response to stress, and are reduced during 
acute infection or trauma (33); the reduction in cord glutamine:glutamate ratio we observed 
in cases vs. controls might therefore reflect greater stress around the time of delivery. These 
associations are intriguing in light of an emerging literature linking reductions in plasma 
glutamine, and in the glutamine:glutamate ratio, to increased risk of diabetes, insulin 
resistance, and hypertension (15), as well as a recent study linking genetic polymorphisms in 
glutamate metabolism to cardiovascular risk in individuals with T2D (34). Because we did 
not measure cord blood insulin or c-peptide levels, we could not directly examine 
associations between infant hyperinsulinemia or cord HOMA-IR and glutamine:glutamate 
ratio, or other metabolites. This will be an important area for future analyses.
Our study has several limitations. First, observational nature of the analysis precludes causal 
inferences. Second, relatively few metabolites were significantly altered by case vs. control 
status – only 16 out of 415 detected metabolites were altered at P<0.05 in our unadjusted 
analysis, and only 17 were significantly altered (P<0.05) after adjustment for covariates. The 
small sample size likely limited our power to detect differences. Clinical heterogeneity 
between groups, such as differences in maternal BMI, may have contributed to differences 
in the cord blood metabolome. Future studies using propensity-matched cases and controls 
could address this possibility. We recognize the possibility that the cord blood metabolome 
may have limited “predictive” significance, instead providing a snapshot of the immediate 
developmental and metabolic status of the infant. This possibility is supported by the 
observation that relatively few metabolites (n=13) were significantly correlated with the 
change in weight from 0-6 months, yet large numbers of cord blood metabolites were 
significantly associated with infant adiposity (n=42) and newborn T4 (n=34) (not shown). It 
is also unclear to what extent the cord blood metabolome is influenced by maternal diet 
immediately prior to delivery as opposed to maternal, fetal or placental metabolism. Despite 
these limitations, pathway analysis allowed us to identify concordant regulation of both 
methyl donor and tryptophan-related metabolites. Some of the strengths include the detailed 
assessments of mothers during pregnancy, and the extensive information captured about 
clinical and environmental factors that may influence childhood obesity risk.
In summary, we examined the cord blood metabolome in infants with and without 
accelerated early childhood weight gain to better understand the nutritional and metabolic 
determinants of early-onset obesity risk. While we found few overall differences in the cord 
metabolome of cases vs. controls, several metabolites linked to tryptophan and one-carbon 
metabolism were significantly reduced in cord blood from cases with accelerated postnatal 
weight gain. Moreover, the ratio of glutamine to glutamate, which has recently been linked 
to insulin resistance and cardiometabolic risk, was lower in cases vs. controls. Our data raise 
the possibility that perturbed metabolite patterns may already be present in cord blood of 
infants at risk for rapid postnatal weight gain, prior to obesity onset. Elucidating the 
mechanistic basis for these metabolite alterations and their potential role in obesity 
pathogenesis will require future study.
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Figure 1. Selected top-ranking metabolites in categorical analysis of cases vs. controls
A. Upregulated metabolites. N=26/group, P<0.05.
B. Methyl donors. N=26/group, P<0.05.
C. Tryptophan derivatives. N=26/group, P<0.05.
D. Plant components. N=26/group, P<0.05.
E. Glutamine to glutamate ratio. N=25 controls and 26 cases, P<0.05.
Open circles denote controls; filled circles denote cases.
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Table 1
Maternal, pregnancy, and early childhood characteristics
Maternal, pregnancy, and early childhood characteristics of 26 cases of accelerated postnatal weight gain and 
26 controls with normal postnatal growth from Project Viva. If not otherwise noted, P-value refers to unpaired 
Student’s T-test. For categorical data, P-value calculated using Fisher’s exact test.
Maternal & pregnancy
characteristics Cases (n=26)
Controls
(n=26) P-value
Mean (SD) or N (%)
Maternal age, years 29.9 (5.4) 34.9 (4.4) 0.001
Race/ethnicity, N (%)
 White 13 (50) 19 (73) 0.13
 Black 8 (31) 6 (23)
 Hispanic 4 (15) 0 (0)
 Other or more than 1 race 1 (4) 1 (4)
Smoking status, N (%)
 Never 17 (65) 19 (73) 0.58
 Former smoker 4 (15) 5 (19)
 Smoked during pregnancy 5 (19) 2 (8)
Pre-pregnancy BMI, kg/m2 27.9 (6.7) 23.6 (3.8) 0.01
Pre-pregnancy BMI category, N
(%)
 Lean 11 (42) 20 (77) 0.04
 Overweight 7 (27) 3 (11.5)
 Obese 8 (31) 3 (11.5)
Gestational weight gain, kg 15.5 (5.5) 15.8 (5.2) 0.82
Glucose challenge test, mg/dl 110 (22) 113 (25) 0.67
Glucose tolerance, N (%)
 Normal 22 (85) 23 (88) 0.7
 GDM 3 (12) 1 (4)
 Transient hyperglycemia 1 (4) 2 (8)
Blood pressure status, N (%)
 Normal blood pressure 19 (79) 24 (96) 0.11
 Gestational hypertension 4 (15) 1 (4)
 Pre-eclampsia 1 (4) 0 (0)
Caesarian delivery
 No, N (%) 22 (85) 22 (85) 1
 Yes, N (%) 4 (15) 4 (15)
Father’s BMI, kg/m2 (SD) 27.6 (3.7) 25.3 (3.5) 0.03
Early childhood characteristics
Gestational age, weeks 39.2 (2.1) 39.8 (1.5) 0.2
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Maternal & pregnancy
characteristics Cases (n=26)
Controls
(n=26) P-value
Neonatal anthropometry
 Birth weight, grams 3275 (458) 3487 (349) 0.07
 Birth weight for gestational age and
sex, Z-score −0.19 (0.79) 0.11 (0.67) 0.15
 Length for age and sex, Z-score −0.38 (0.81) 0.00 (0.58) 0.16
 Weight for length, Z-score 0.37 (0.94) 0.43 (0.78) 0.85
Breastfeeding duration, months 4.0 (3.1) 8.2 (4.0) 0.0002
Thyroid hormone (T4), microg/dl,
newborn 18.7 (6.1) 17.8 (3.9) 0.68
Leptin, ng/ml, cord blood 6.4 (3.3) 8.0 (4.9) 0.19
Adiponectin, microg/ml, cord
blood 27.4 (6.3) 26.9 (7.9) 0.83
Anthropometry, age 6 months
 Weight for age, Z-score 1.25 (0.86) 0.26 (0.59) <0.0001
 Length for age, Z-score 0.19 (1.22) −0.19 (0.75) 0.21
 Weight for length, Z-score 1.52 (1.00) 0.74 (0.60) 0.002
 Change in weight for age Z-score 0-6
mo 1.64 (0.66) 0.24 (0.41) <0.0001
Anthropometry at mid-childhood
 Weight, kg 40.6 (12.8) 26.4 (3.4) <0.0001
 Height, cm 132.2 (10.1) 128.5 (6.6) 0.12
 BMI, percentile 95.5 (4.7) 51.5 (15.5) <0.0001
 Total fat mass (DEXA), kg 13.2 (4.7) 6.0 (1.2) <0.0001
 Total lean mass (DEXA), kg 16.6 (5.4) 20.4 (3.1) <0.0001
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Table 2
Top-ranking cord blood metabolites altered in cases vs. controls
A. Log2-transformed metabolite levels (missing values replaced with 0.5*minimum value detected) in cord blood from 26 cases of 
accelerated early postnatal weight gain and 26 controls with normal growth trajectories from Project Viva. Shown are the 16 
metabolites with unadjusted P<0.05, out of the 415 metabolites detected. Fold-change was calculated as [2^(log mean Cases)]/[2^(log 
mean Controls)].
Cases Controls
Fold-
change P-valuve FDR
BIOCHEMICAL N
Mean
(SD) N
Mean
(SD)
Case/
Control Unadjusted ** Adjusted ***
Q-
value
Homostachydrine 22
14.33
(0.82) 16
13.71
(0.78) 1.54 0.007 0.02 0.97
4-vinylphenol sulfate 26
15.8
(1.39) 26
16.81
(1.27) 0.5 0.009 0.04 0.97
Dimethylglycine 26
18.88
(0.45) 26
19.17
(0.34) 0.82 0.01 0.14 0.97
N-acetylmethionine 26
15.06
(0.36) 26
15.32
(0.36) 0.84 0.01 0.01 0.97
Threonine 26
18.50
(0.30) 26
18.31
(0.25) 1.14 0.02 0.23 0.97
Serotonin (5HT) 12 *
14.08
(1.31) 20
14.96
(1.32) 0.54 0.02 0.03 0.97
Pyridoxate 26
17.26
(1.51) 26
18.08
(0.91) 0.57 0.02 0.11 0.97
3-carboxy-4-methyl-5-propyl-
2-furanpropanoate (CMPF) 26 17.40(1.51) 26
18.27
(1.15) 0.55 0.02 0.45 0.97
Tryptophylleucine 25
15.43
(0.79) 26
15.87
(0.58) 0.74 0.03 0.02 0.97
Tryptophan betaine 25
18.42
(1.96) 26
19.37
(0.86) 0.52 0.03 0.22 0.97
Sphingosine 26
17.56
(0.94) 26
18.13
(0.94) 0.68 0.03 0.08 0.97
Maltose 22
18.83
(1.56) 26
19.67
(1.22) 0.56 0.03 0.12 0.97
N-methyl proline 11 *
13.80
(1.60) 19
14.70
(1.53) 0.54 0.04 0.74 0.97
Alanylalanine 10
11.40
(1.63) 17
12.35
(1.71) 0.52 0.04 0.28 0.97
2-docosahexaenoyl-
glycerophosphocholine 26
18.31
(0.36) 26
18.53
(0.41) 0.86 0.04 0.06 0.97
1-stearoyl-glycerophosphoethanolamine 25
18.35
(0.84) 26
18.79
(0.72) 0.73 0.05 0.04 0.97
B. Log-2 transformed mean metabolite levels in cord blood from 26 cases of accelerated early postnatal weight gain and 26 controls 
with normal growth trajectories from Project Viva, adjusted for maternal BMI, maternal age, and infant breastfeeding duration. 
Shown are the 17 metabolites with adjusted P<0.05, out of the 415 metabolites detected. Fold-change was calculated as [2^(log mean 
Cases)]/[2^(log mean Controls)].
Cases Conntrol
Fold
Change P-value FDR
BIOCHEMICAL N
Mean
(SD) N
Mean
(SD)
Case/
control Unadjusted ** Adjusted ***
Q-
value
Alpha-hydroxyisovalerate 26
20.30
(0.52) 26
20.54
(0.34) 0.85 0.06 0.005 0.97
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B. Log-2 transformed mean metabolite levels in cord blood from 26 cases of accelerated early postnatal weight gain and 26 controls 
with normal growth trajectories from Project Viva, adjusted for maternal BMI, maternal age, and infant breastfeeding duration. 
Shown are the 17 metabolites with adjusted P<0.05, out of the 415 metabolites detected. Fold-change was calculated as [2^(log mean 
Cases)]/[2^(log mean Controls)].
Cases Conntrol
Fold
Change P-value FDR
BIOCHEMICAL N
Mean
(SD) N
Mean
(SD)
Case/
control Unadjusted ** Adjusted ***
Q-
value
N-acetylmethionine 26
15.06
(0.36) 26
15.32
(0.36) 0.84 0.01 0.01 0.97
Homostachydrine 22
14.33
(0.82) 16
13.71
(0.78) 1.54 0.01 0.02 0.97
Erythro-sphingosine-1-
phosphate 25
16.43
(0.84) 26
16.75
(0.74) 0.8 0.15 0.02 0.97
Tryptophylleucine 25
15.43
(0.79) 26
15.87
(0.58) 0.74 0.03 0.02 0.97
Serotonin (5HT) 12 *
14.08
(1.31) 20
14.96
(1.32) 0.54 0.02 0.03 0.97
Beta-alanine 19 *
14.76
(1.35) 25
15.39
(0.84) 0.65 0.05 0.03 0.97
Tryptophan 26
24.22
(0.26) 26
24.32
(0.24) 0.94 0.17 0.03 0.97
2-aminobutyrate 26
18.59
(0.42) 26
18.64
(0.27) 0.97 0.65 0.03 0.97
Alpha-hydroxyisocaproate 26
13.72
(0.81) 26
13.90
(0.84) 0.88 0.44 0.04 0.97
Nicotinamide 26
16.75
(0.82) 26
17.08
(0.53) 0.8 0.09 0.04 0.97
Leucine 26
24.18
(0.28) 26
24.23
(0.21) 0.97 0.47 0.04 0.97
4-vinylphenol sulfate 20
15.80
(1.39) 26
16.81
(1.27) 0.5 0.01 0.01 0.97
N-acetyltryptophan 19
12.31
(1.16) 24
12.47
(0.74) 0.89 0.54 0.04 0.97
1-stearoyl-glycerophosphoethanolamine 25
18.35
(0.84) 26
18.79
(0.72) 0.73 0.05 0.04 0.97
Caprylate (8:0) 26
17.39
(0.41) 26
17.57
(0.40) 0.88 0.11 0.05 0.97
Indolelactate 26
19.89
(0.40) 26
19.96
(0.33) 0.95 0.46 0.05 0.97
*
refers to metabolites for which the number of detectable samples (N) differed between cases and controls (Fisher’s exact test).
**Unadjusted P-value refers to T-test in cases vs. controls.
***Adjusted P-value derived from linear regression, adjusted for maternal age, BMI and child breastfeeding duration.
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Table 3
Associations of maternal and infant characteristics with odds of case vs. control status
A. Bivariate logistic regression models of parental and perinatal covariates associated with odds of case vs. 
control status. B. Multivariable logistic regression models incorporating clinical and metabolite data.
A: Bivariate logistic regression
Covariate OR (95% CI) P
Breastfeeding duration, months 0.74 (0.62-0.89) 0.001
Mat age at enrollment, years 0.81 (0.71-0.93) 0.003
Maternal pre-pregnancy BMI, kg/m2 1.19 (1.04-1.36) 0.01
Father’s BMI, kg/m2 1.21 (1.01-1.45) 0.04
Birth weight, grams 1 (1.00-1.00) 0.08
Non-white race/ethnicity 2.71 (0.85-8.64) 0.09
Birth weight for gestational age and sex, Z-score 0.56 (0.26-1.23) 0.15
Leptin, ng/ml, cord blood 0.91 (0.79-1.05) 0.19
Gestational age at delivery, wks 0.80 (0.56-1.14) 0.21
T4, microg/dl, newborn 1.04 (0.88-1.23) 0.64
Glucose, maternal 0.99 (0.97-1.02) 0.66
Gestational weight gain, kg 0.99 (0.89-1.10) 0.81
Adiponectin, microg/ml, cord blood 1.01 (0.93-1.09) 0.82
Newborn weight for length, Z-score 0.91 (0.39-2.15) 0.84
B: Multivariate logistic regression
Model OR (95% CI) P (chi-square)
Model A: R2 = 0.39, P<0.0001
 Maternal age at enrollment, years 0.83 (0.68-0.98) 0.02
 Maternal pre-pregnancy BMI, kg/m2 1.21 (1.04-1.49) 0.01
 Breastfeeding duration, months 0.73 (0.57-0.89) 0.001
Model A + homostachydrine: R2 = 0.46, P<0.0001
 Homostachydrine 3.72 (1.20-15.7) 0.04
Model A + N-acetylmethionine: R2 = 0.54, P<0.0001
 N-acetylmethionine 0.006 (5.3×10−5-0.17) 0.01
Model A + tryptophyl leucine: R2 = 0.47, P<0.0001
 Tryptophyl leucine 0.18 (0.03-0.76) 0.04
Model A + 1-stearoyl-GPE: R2 = 0.49, P<0.0001
 1-stearoyl-GPE 0.19 (0.03-0.66) 0.02
Model A + alpha-hydroxyisovalerate: R2 = 0.53,
P<0.0001
 Alpha-hydroxyisovalerate 0.02 (0.0002-0.26) 0.02
Model A + tryptophan: R2 = 0.45, P<0.0001
 Tryptophan 0.03 (0.0004-0.71) 0.047
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B: Multivariate logistic regression
Model OR (95% CI) P (chi-square)
Model A + 2-aminobutyrate: R2 = 0.47, P<0.0001
2-aminobutyrate 0.04 (0.002 – 0.59) 0.03
Model A + alpha-hydroxyisocaproate: R2 = 0.46,
P<0.0001
 Alpha-hydroxyisocaproate 0.28 (0.07-0.87) 0.04
Model A + nicotinamide: R2 = 0.46, P<0.0001
 Nicotinamide 0.26 (0.07-0.81) 0.03
Model A + leucine: R2 = 0.44, P<0.0001
 Leucine 0.04 (0.001-0.91) 0.046
Model A + indolelactate: R2 = 0.45, P<0.0001
 Indolelactate 0.09 (0.007-0.81) 0.046
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